结肠癌的综合概述——21 世纪的死神

Nguyen, H.T.; Duong, H-Q. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol. Lett., 2018, 16(1), 9-18.
[http://dx.doi.org/10.3892/ol.2018.8679] [PMID: 29928381]

Punt, C.J.; Koopman, M.; Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol., 2017, 14(4), 235-246.
[http://dx.doi.org/10.1038/nrclinonc.2016.171] [PMID: 27922044]

Vermeulen, L.; Morrissey, E.; van der Heijden, M.; Nicholson, A.M.; Sottoriva, A.; Buczacki, S.; Kemp, R.; Tavaré, S.; Winton, D.J. Defining stem cell dynamics in models of intestinal tumor initiation. Science, 2013, 342(6161), 995-998.
[http://dx.doi.org/10.1126/science.1243148] [PMID: 24264992]

Fearon, E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol., 2011, 6, 479-507.
[http://dx.doi.org/10.1146/annurev-pathol-011110-130235] [PMID: 21090969]

Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med., 2009, 361(25), 2449-2460.
[http://dx.doi.org/10.1056/NEJMra0804588] [PMID: 20018966]

IJspeert, J.E.; Vermeulen, L.; Meijer, G.A.; Dekker, E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat. Rev. Gastroenterol. Hepatol., 2015, 12(7), 401-409.
[http://dx.doi.org/10.1038/nrgastro.2015.73] [PMID: 25963511]

Leedham, S.J.; Graham, T.A.; Oukrif, D.; McDonald, S.A.; Rodriguez-Justo, M.; Harrison, R.F.; Shepherd, N.A.; Novelli, M.R.; Jankowski, J.A.; Wright, N.A. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology, 2009, 136(2), 542-50.e6.
[http://dx.doi.org/10.1053/j.gastro.2008.10.086] [PMID: 19103203]

Hussain, S.P.; Amstad, P.; Raja, K.; Ambs, S.; Nagashima, M.; Bennett, W.P.; Shields, P.G.; Ham, A-J.; Swenberg, J.A.; Marrogi, A.J.; Harris, C.C. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res., 2000, 60(13), 3333-3337.

Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
[http://dx.doi.org/10.1056/NEJMoa032691] [PMID: 15175435]

Papamichael, D.; Audisio, R.A.; Glimelius, B.; de Gramont, A.; Glynne-Jones, R.; Haller, D.; Köhne, C-H.; Rostoft, S.; Lemmens, V.; Mitry, E.; Rutten, H.; Sargent, D.; Sastre, J.; Seymour, M.; Starling, N.; Van Cutsem, E.; Aapro, M. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann. Oncol., 2015, 26(3), 463-476.
[http://dx.doi.org/10.1093/annonc/mdu253] [PMID: 25015334]

Valori, R.; Rey, J-F.; Atkin, W.S.; Bretthauer, M.; Senore, C.; Hoff, G.; Kuipers, E.J.; Altenhofen, L.; Lambert, R.; Minoli, G. International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis-- Quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy, 2012, 44(S03), SE88-SE105.
[http://dx.doi.org/10.1055/s-0032-1309795] [PMID: 23012124]

O’Keefe, S.J. Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol., 2016, 13(12), 691-706.
[http://dx.doi.org/10.1038/nrgastro.2016.165] [PMID: 27848961]

Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci., 2017, 18(1), 197.
[http://dx.doi.org/10.3390/ijms18010197] [PMID: 28106826]

Özdemir, Z.; Utku, S.; Mathew, B.; Carradori, S.; Orlando, G.; Di Simone, S.; Alagöz, M.A.; Özçelik, A.B.; Uysal, M.; Ferrante, C. Synthesis and biological evaluation of new 3(2H)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells. J. Enzyme Inhib. Med. Chem., 2020, 35(1), 1100-1109.
[http://dx.doi.org/10.1080/14756366.2020.1755670] [PMID: 32321320]

Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.R.M.R.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.E.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M.F.; Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.P.V.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Shantha Kumara, H.M.C.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompso, S.K.; Tran, P.T.; Ungefroren, H.; Vander Heiden, M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35 Suppl(Suppl), S276-S304.
[http://dx.doi.org/10.1016/j.semcancer.2015.09.007] [PMID: 26590477]

Colon Cancer Treatment (PDQ^®)-Health Professional Version - National Cancer Institute. Available at: https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq (Accessed date: August 30, 2020).

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]

Guren, M.G. The global challenge of colorectal cancer. Lancet Gastroenterol. Hepatol., 2019, 4(12), 894-895.
[http://dx.doi.org/10.1016/S2468-1253(19)30329-2] [PMID: 31648973]

Cancer today. Available at: http://gco.iarc.fr/today/ home (Accessed date: Aug 30, 2020).

Capelle, L.G.; Van Grieken, N.C.; Lingsma, H.F.; Steyerberg, E.W.; Klokman, W.J.; Bruno, M.J.; Vasen, H.F.; Kuipers, E.J. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology, 2010, 138(2), 487-492.
[http://dx.doi.org/10.1053/j.gastro.2009.10.051] [PMID: 19900449]

Kuipers, E.J.; Grady, W.M.; Lieberman, D.; Seufferlein, T.; Sung, J.J.; Boelens, P.G.; van de Velde, C.J.H.; Watanabe, T. Colorectal cancer. Nat. Rev. Dis. Primers, 2015, 1, 15065.
[http://dx.doi.org/10.1038/nrdp.2015.65] [PMID: 27189416]

Vasen, H.F.; Tomlinson, I.; Castells, A. Clinical management of hereditary colorectal cancer syndromes. Nat. Rev. Gastroenterol. Hepatol., 2015, 12(2), 88-97.
[http://dx.doi.org/10.1038/nrgastro.2014.229] [PMID: 25582351]

Ait Ouakrim, D.; Pizot, C.; Boniol, M.; Malvezzi, M.; Boniol, M.; Negri, E.; Bota, M.; Jenkins, M.A.; Bleiberg, H.; Autier, P. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ, 2015, 351, h4970.
[http://dx.doi.org/10.1136/bmj.h4970] [PMID: 26442928]

Welch, H.G.; Robertson, D.J. Colorectal cancer on the decline--why screening can’t explain it all. N. Engl. J. Med., 2016, 374(17), 1605-1607.
[http://dx.doi.org/10.1056/NEJMp1600448] [PMID: 27119236]

Mendelsohn, R.B.; Winawer, S.J.; Ahnen, D.J. Incidence of colorectal cancer matters. Gastroenterology, 2020, 158(5), 1191-1195.
[http://dx.doi.org/10.1053/j.gastro.2019.11.304] [PMID: 31863742]

Bailey, C.E.; Hu, C-Y.; You, Y.N.; Bednarski, B.K.; Rodriguez-Bigas, M.A.; Skibber, J.M.; Cantor, S.B.; Chang, G.J. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg., 2015, 150(1), 17-22.
[http://dx.doi.org/10.1001/jamasurg.2014.1756] [PMID: 25372703]

Wolf, A.M.D.; Fontham, E.T.H.; Church, T.R.; Flowers, C.R.; Guerra, C.E.; LaMonte, S.J.; Etzioni, R.; McKenna, M.T.; Oeffinger, K.C.; Shih, Y.T.; Walter, L.C.; Andrews, K.S.; Brawley, O.W.; Brooks, D.; Fedewa, S.A.; Manassaram-Baptiste, D.; Siegel, R.L.; Wender, R.C.; Smith, R.A. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin., 2018, 68(4), 250-281.
[http://dx.doi.org/10.3322/caac.21457] [PMID: 29846947]

Kasi, P.M.; Shahjehan, F.; Cochuyt, J.J.; Li, Z.; Colibaseanu, D.T.; Merchea, A. Rising proportion of young individuals with rectal and colon cancer. Clin. Colorectal Cancer, 2019, 18(1), e87-e95.
[http://dx.doi.org/10.1016/j.clcc.2018.10.002] [PMID: 30420120]

Keum, N.; Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(12), 713-732.
[http://dx.doi.org/10.1038/s41575-019-0189-8] [PMID: 31455888]

Henrikson, N.B.; Webber, E.M.; Goddard, K.A.; Scrol, A.; Piper, M.; Williams, M.S.; Zallen, D.T.; Calonge, N.; Ganiats, T.G.; Janssens, A.C.J.; Zauber, A.; Lansdorp-Vogelaar, I.; van Ballegooijen, M.; Whitlock, E.P. Family history and the natural history of colorectal cancer: systematic review. Genet. Med., 2015, 17(9), 702-712.
[http://dx.doi.org/10.1038/gim.2014.188] [PMID: 25590981]

Schoen, R.E.; Razzak, A.; Yu, K.J.; Berndt, S.I.; Firl, K.; Riley, T.L.; Pinsky, P.F. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology, 2015, 149(6), 1438-1445.e1.
[http://dx.doi.org/10.1053/j.gastro.2015.07.055] [PMID: 26255045]

Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet, 2019, 394(10207), 1467-1480.
[http://dx.doi.org/10.1016/S0140-6736(19)32319-0] [PMID: 31631858]

Jiao, S.; Peters, U.; Berndt, S.; Brenner, H.; Butterbach, K.; Caan, B.J.; Carlson, C.S.; Chan, A.T.; Chang-Claude, J.; Chanock, S.; Curtis, K.R.; Duggan, D.; Gong, J.; Harrison, T.A.; Hayes, R.B.; Henderson, B.E.; Hoffmeister, M.; Kolonel, L.N.; Le Marchand, L.; Potter, J.D.; Rudolph, A.; Schoen, R.E.; Seminara, D.; Slattery, M.L.; White, E.; Hsu, L. Estimating the heritability of colorectal cancer. Hum. Mol. Genet., 2014, 23(14), 3898-3905.
[http://dx.doi.org/10.1093/hmg/ddu087] [PMID: 24562164]

Syngal, S.; Brand, R.E.; Church, J.M.; Giardiello, F.M.; Hampel, H.L.; Burt, R.W. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol., 2015, 110(2), 223-262.
[http://dx.doi.org/10.1038/ajg.2014.435] [PMID: 25645574]

Cottet, V.; Jooste, V.; Fournel, I.; Bouvier, A-M.; Faivre, J.; Bonithon-Kopp, C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut, 2012, 61(8), 1180-1186.
[http://dx.doi.org/10.1136/gutjnl-2011-300295] [PMID: 22110052]

Jess, T.; Rungoe, C.; Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol., 2012, 10(6), 639-645.
[http://dx.doi.org/10.1016/j.cgh.2012.01.010] [PMID: 22289873]

Vasen, H.F.A.; Blanco, I.; Aktan-Collan, K.; Gopie, J.P.; Alonso, A.; Aretz, S.; Bernstein, I.; Bertario, L.; Burn, J.; Capella, G.; Colas, C.; Engel, C.; Frayling, I.M.; Genuardi, M.; Heinimann, K.; Hes, F.J.; Hodgson, S.V.; Karagiannis, J.A.; Lalloo, F.; Lindblom, A.; Mecklin, J-P.; Møller, P.; Myrhoj, T.; Nagengast, F.M.; Parc, Y.; Ponz de Leon, M.; Renkonen-Sinisalo, L.; Sampson, J.R.; Stormorken, A.; Sijmons, R.H.; Tejpar, S.; Thomas, H.J.W.; Rahner, N.; Wijnen, J.T.; Järvinen, H.J.; Möslein, G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62(6), 812-823.
[http://dx.doi.org/10.1136/gutjnl-2012-304356] [PMID: 23408351]

Botteri, E.; Iodice, S.; Bagnardi, V.; Raimondi, S.; Lowenfels, A.B.; Maisonneuve, P. Smoking and colorectal cancer: a meta-analysis. JAMA, 2008, 300(23), 2765-2778.
[http://dx.doi.org/10.1001/jama.2008.839] [PMID: 19088354]

Kyrgiou, M.; Kalliala, I.; Markozannes, G.; Gunter, M.J.; Paraskevaidis, E.; Gabra, H.; Martin-Hirsch, P.; Tsilidis, K.K. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ, 2017, 356, j477.
[http://dx.doi.org/10.1136/bmj.j477] [PMID: 28246088]

Cai, S.; Li, Y.; Ding, Y.; Chen, K.; Jin, M. Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. Eur. J. Cancer Prev., 2014, 23(6), 532-539.
[http://dx.doi.org/10.1097/CEJ.0000000000000076] [PMID: 25170915]

Chan, D.S.M.; Lau, R.; Aune, D.; Vieira, R.; Greenwood, D.C.; Kampman, E.; Norat, T. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One, 2011, 6(6), e20456.
[http://dx.doi.org/10.1371/journal.pone.0020456] [PMID: 21674008]

Krämer, H.U.; Schöttker, B.; Raum, E.; Brenner, H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur. J. Cancer, 2012, 48(9), 1269-1282.
[http://dx.doi.org/10.1016/j.ejca.2011.07.010] [PMID: 21889332]

Nakatsu, G.; Li, X.; Zhou, H.; Sheng, J.; Wong, S.H.; Wu, W.K.K.; Ng, S.C.; Tsoi, H.; Dong, Y.; Zhang, N.; He, Y.; Kang, Q.; Cao, L.; Wang, K.; Zhang, J.; Liang, Q.; Yu, J.; Sung, J.J.Y. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun., 2015, 6(1), 8727.
[http://dx.doi.org/10.1038/ncomms9727] [PMID: 26515465]

Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; El-Omar, E.M.; Brenner, D.; Fuchs, C.S.; Meyerson, M.; Garrett, W.S. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe, 2013, 14(2), 207-215.
[http://dx.doi.org/10.1016/j.chom.2013.07.007] [PMID: 23954159]

Yu, A.I.; Zhao, L.; Eaton, K.A.; Ho, S.; Chen, J.; Poe, S.; Becker, J.; Gonzalez, A.; McKinstry, D.; Hasso, M.; Mendoza-Castrejon, J.; Whitfield, J.; Koumpouras, C.; Schloss, P.D.; Martens, E.C.; Chen, G.Y. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep., 2020, 31(1), 107471.
[http://dx.doi.org/10.1016/j.celrep.2020.03.035] [PMID: 32268087]

Tomasello, G.; Tralongo, P.; Damiani, P.; Sinagra, E.; Di Trapani, B.; Zeenny, M.N.; Hussein, I.H.; Jurjus, A.; Leone, A. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J. Gastroenterol., 2014, 20(48), 18121-18130.
[http://dx.doi.org/10.3748/wjg.v20.i48.18121] [PMID: 25561781]

Chai, E.Z.P.; Siveen, K.S.; Shanmugam, M.K.; Arfuso, F.; Sethi, G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem. J., 2015, 468(1), 1-15.
[http://dx.doi.org/10.1042/BJ20141337] [PMID: 25940732]

Sobhani, I.; Amiot, A.; Le Baleur, Y.; Levy, M.; Auriault, M-L.; Van Nhieu, J.T.; Delchier, J.C. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap. Adv. Gastroenterol., 2013, 6(3), 215-229.
[http://dx.doi.org/10.1177/1756283X12473674] [PMID: 23634186]

Candela, M.; Turroni, S.; Biagi, E.; Carbonero, F.; Rampelli, S.; Fiorentini, C.; Brigidi, P. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J. Gastroenterol., 2014, 20(4), 908-922.
[http://dx.doi.org/10.3748/wjg.v20.i4.908] [PMID: 24574765]

Zackular, J.P.; Baxter, N.T.; Iverson, K.D.; Sadler, W.D.; Petrosino, J.F.; Chen, G.Y.; Schloss, P.D. The gut microbiome modulates colon tumorigenesis. MBio, 2013, 4(6), e00692-e13.
[http://dx.doi.org/10.1128/mBio.00692-13] [PMID: 24194538]

Wong, S.H.; Yu, J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(11), 690-704.
[http://dx.doi.org/10.1038/s41575-019-0209-8] [PMID: 31554963]

Saus, E.; Iraola-Guzmán, S.; Willis, J.R.; Brunet-Vega, A.; Gabaldón, T. Microbiome and colorectal cancer: roles in carcinogenesis and clinical potential. Mol. Aspects Med., 2019, 69, 93-106.
[http://dx.doi.org/10.1016/j.mam.2019.05.001] [PMID: 31082399]

Nosho, K.; Sukawa, Y.; Adachi, Y.; Ito, M.; Mitsuhashi, K.; Kurihara, H.; Kanno, S.; Yamamoto, I.; Ishigami, K.; Igarashi, H.; Maruyama, R.; Imai, K.; Yamamoto, H.; Shinomura, Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol., 2016, 22(2), 557-566.
[http://dx.doi.org/10.3748/wjg.v22.i2.557] [PMID: 26811607]

Bashir, A.; Miskeen, A.Y.; Hazari, Y.M.; Asrafuzzaman, S.; Fazili, K.M. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol., 2016, 37(3), 2805-2810.
[http://dx.doi.org/10.1007/s13277-015-4724-0] [PMID: 26718210]

Allen-Vercoe, E.; Jobin, C. Fusobacterium and Enterobacteriaceae: important players for CRC? Immunol. Lett., 2014, 162(2 Pt A), 54-61.
[http://dx.doi.org/10.1016/j.imlet.2014.05.014] [PMID: 24972311]

Sears, C.L.; Geis, A.L.; Housseau, F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J. Clin. Invest., 2014, 124(10), 4166-4172.
[http://dx.doi.org/10.1172/JCI72334] [PMID: 25105360]

Chen, H.D.; Frankel, G. Enteropathogenic Escherichia coli: unravelling pathogenesis. FEMS Microbiol. Rev., 2005, 29(1), 83-98.
[http://dx.doi.org/10.1016/j.femsre.2004.07.002] [PMID: 15652977]

Choi, H.J.; Kim, J.; Do, K.H.; Park, S.H.; Moon, Y. Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene, 2013, 32(41), 4960-4969.
[http://dx.doi.org/10.1038/onc.2012.508] [PMID: 23503457]

Bonnet, M.; Buc, E.; Sauvanet, P.; Darcha, C.; Dubois, D.; Pereira, B.; Déchelotte, P.; Bonnet, R.; Pezet, D.; Darfeuille-Michaud, A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin. Cancer Res., 2014, 20(4), 859-867.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1343] [PMID: 24334760]

Macfarlane, G.T.; Gibson, G.R.; Cummings, J.H. Comparison of fermentation reactions in different regions of the human colon. J. Appl. Bacteriol., 1992, 72(1), 57-64.
[http://dx.doi.org/10.1111/j.1365-2672.1992.tb04882.x] [PMID: 1541601]

Windey, K.; De Preter, V.; Verbeke, K. Relevance of protein fermentation to gut health. Mol. Nutr. Food Res., 2012, 56(1), 184-196.
[http://dx.doi.org/10.1002/mnfr.201100542] [PMID: 22121108]

den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D-J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res., 2013, 54(9), 2325-2340.
[http://dx.doi.org/10.1194/jlr.R036012] [PMID: 23821742]

Parada Venegas, D.; De la Fuente, M.K.; Landskron, G.; González, M-J.; Quera, R.; Dijkstra, G.; Harmsen, H.J.M.; Faber, K.N.; Hermoso, M.A. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol., 2019, 10, 277.
[http://dx.doi.org/10.3389/fimmu.2019.00277] [PMID: 30915065]

Liu, H.; Wang, J.; He, T.; Becker, S.; Zhang, G.; Li, D.; Ma, X. Butyrate: a double-edged sword for health? Adv. Nutr., 2018, 9(1), 21-29.
[http://dx.doi.org/10.1093/advances/nmx009] [PMID: 29438462]

Sakata, T. Pitfalls in short-chain fatty acid research: a methodological review. Anim. Sci. J., 2019, 90(1), 3-13.
[http://dx.doi.org/10.1111/asj.13118] [PMID: 30370625]

Taira, T.; Yamaguchi, S.; Takahashi, A.; Okazaki, Y.; Yamaguchi, A.; Sakaguchi, H.; Chiji, H. Dietary polyphenols increase fecal mucin and immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high fat diet. J. Clin. Biochem. Nutr., 2015, 57(3), 212-216.
[http://dx.doi.org/10.3164/jcbn.15-15] [PMID: 26566306]

Hodge, A.M.; Williamson, E.J.; Bassett, J.K.; MacInnis, R.J.; Giles, G.G.; English, D.R. Dietary and biomarker estimates of fatty acids and risk of colorectal cancer. Int. J. Cancer, 2015, 137(5), 1224-1234.
[http://dx.doi.org/10.1002/ijc.29479] [PMID: 25683336]

Simopoulos, A.P. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed. Pharmacother., 2006, 60(9), 502-507.
[http://dx.doi.org/10.1016/j.biopha.2006.07.080] [PMID: 17045449]

Corley, D.A.; Jensen, C.D.; Marks, A.R.; Zhao, W.K.; Lee, J.K.; Doubeni, C.A.; Zauber, A.G.; de Boer, J.; Fireman, B.H.; Schottinger, J.E.; Quinn, V.P.; Ghai, N.R.; Levin, T.R.; Quesenberry, C.P. Adenoma detection rate and risk of colorectal cancer and death. N. Engl. J. Med., 2014, 370(14), 1298-1306.
[http://dx.doi.org/10.1056/NEJMoa1309086] [PMID: 24693890]

Beets-Tan, R.G.H.; Lambregts, D.M.J.; Maas, M.; Bipat, S.; Barbaro, B.; Curvo-Semedo, L.; Fenlon, H.M.; Gollub, M.J.; Gourtsoyianni, S.; Halligan, S.; Hoeffel, C.; Kim, S.H.; Laghi, A.; Maier, A.; Rafaelsen, S.R.; Stoker, J.; Taylor, S.A.; Torkzad, M.R.; Blomqvist, L. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur. Radiol., 2018, 28(4), 1465-1475.
[http://dx.doi.org/10.1007/s00330-017-5026-2] [PMID: 29043428]

Nerad, E.; Lahaye, M.J.; Maas, M.; Nelemans, P.; Bakers, F.C.H.; Beets, G.L.; Beets-Tan, R.G.H. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. AJR Am. J. Roentgenol., 2016, 207(5), 984-995.
[http://dx.doi.org/10.2214/AJR.15.15785] [PMID: 27490941]

Pagès, F.; Mlecnik, B.; Marliot, F.; Bindea, G.; Ou, F-S.; Bifulco, C.; Lugli, A.; Zlobec, I.; Rau, T.T.; Berger, M.D.; Nagtegaal, I.D.; Vink-Börger, E.; Hartmann, A.; Geppert, C.; Kolwelter, J.; Merkel, S.; Grützmann, R.; Van den Eynde, M.; Jouret-Mourin, A.; Kartheuser, A.; Léonard, D.; Remue, C.; Wang, J.Y.; Bavi, P.; Roehrl, M.H.A.; Ohashi, P.S.; Nguyen, L.T.; Han, S.; MacGregor, H.L.; Hafezi-Bakhtiari, S.; Wouters, B.G.; Masucci, G.V.; Andersson, E.K.; Zavadova, E.; Vocka, M.; Spacek, J.; Petruzelka, L.; Konopasek, B.; Dundr, P.; Skalova, H.; Nemejcova, K.; Botti, G.; Tatangelo, F.; Delrio, P.; Ciliberto, G.; Maio, M.; Laghi, L.; Grizzi, F.; Fredriksen, T.; Buttard, B.; Angelova, M.; Vasaturo, A.; Maby, P.; Church, S.E.; Angell, H.K.; Lafontaine, L.; Bruni, D.; El Sissy, C.; Haicheur, N.; Kirilovsky, A.; Berger, A.; Lagorce, C.; Meyers, J.P.; Paustian, C.; Feng, Z.; Ballesteros-Merino, C.; Dijkstra, J.; van de Water, C.; van Lent-van Vliet, S.; Knijn, N.; Mușină, A-M.; Scripcariu, D-V.; Popivanova, B.; Xu, M.; Fujita, T.; Hazama, S.; Suzuki, N.; Nagano, H.; Okuno, K.; Torigoe, T.; Sato, N.; Furuhata, T.; Takemasa, I.; Itoh, K.; Patel, P.S.; Vora, H.H.; Shah, B.; Patel, J.B.; Rajvik, K.N.; Pandya, S.J.; Shukla, S.N.; Wang, Y.; Zhang, G.; Kawakami, Y.; Marincola, F.M.; Ascierto, P.A.; Sargent, D.J.; Fox, B.A.; Galon, J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 2018, 391(10135), 2128-2139.
[http://dx.doi.org/10.1016/S0140-6736(18)30789-X] [PMID: 29754777]

Sargent, D.J.; Marsoni, S.; Monges, G.; Thibodeau, S.N.; Labianca, R.; Hamilton, S.R.; French, A.J.; Kabat, B.; Foster, N.R.; Torri, V.; Ribic, C.; Grothey, A.; Moore, M.; Zaniboni, A.; Seitz, J-F.; Sinicrope, F.; Gallinger, S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol., 2010, 28(20), 3219-3226.
[http://dx.doi.org/10.1200/JCO.2009.27.1825] [PMID: 20498393]

Li, W.; Li, H.; Liu, R.; Yang, X.; Gao, Y.; Niu, Y.; Geng, J.; Xue, Y.; Jin, X.; You, Q.; Geng, J.; Meng, H. Comprehensive analysis of the relationship between RAS and RAF mutations and MSI status of colorectal cancer in northeastern China. Cell. Physiol. Biochem., 2018, 50(4), 1496-1509.
[http://dx.doi.org/10.1159/000494649] [PMID: 30359964]

Warren, J.D.; Xiong, W.; Bunker, A.M.; Vaughn, C.P.; Furtado, L.V.; Roberts, W.L.; Fang, J.C.; Samowitz, W.S.; Heichman, K.A. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med., 2011, 9(1), 133.
[http://dx.doi.org/10.1186/1741-7015-9-133] [PMID: 22168215]

Kin, C.; Kidess, E.; Poultsides, G.A.; Visser, B.C.; Jeffrey, S.S. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev. Mol. Diagn., 2013, 13(6), 581-599.
[http://dx.doi.org/10.1586/14737159.2013.811896] [PMID: 23895128]

Barbany, G.; Arthur, C.; Liedén, A.; Nordenskjöld, M.; Rosenquist, R.; Tesi, B.; Wallander, K.; Tham, E. Cell-free tumour DNA testing for early detection of cancer - a potential future tool. J. Intern. Med., 2019, 286(2), 118-136.
[http://dx.doi.org/10.1111/joim.12897] [PMID: 30861222]

Hayashi, N.; Tanaka, S.; Hewett, D.G.; Kaltenbach, T.R.; Sano, Y.; Ponchon, T.; Saunders, B.P.; Rex, D.K.; Soetikno, R.M. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. Gastrointest. Endosc., 2013, 78(4), 625-632.
[http://dx.doi.org/10.1016/j.gie.2013.04.185] [PMID: 23910062]

Law, R.; Das, A.; Gregory, D.; Komanduri, S.; Muthusamy, R.; Rastogi, A.; Vargo, J.; Wallace, M.B.; Raju, G.S.; Mounzer, R.; Klapman, J.; Shah, J.; Watson, R.; Wilson, R.; Edmundowicz, S.A.; Wani, S. Endoscopic resection is cost-effective compared with laparoscopic resection in the management of complex colon polyps: an economic analysis. Gastrointest. Endosc., 2016, 83(6), 1248-1257.
[http://dx.doi.org/10.1016/j.gie.2015.11.014] [PMID: 26608129]

Raju, G.S.; Lum, P.J.; Ross, W.A.; Thirumurthi, S.; Miller, E.; Lynch, P.M.; Lee, J.H.; Bhutani, M.S.; Shafi, M.A.; Weston, B.R.; Pande, M.; Bresalier, R.S.; Rashid, A.; Mishra, L.; Davila, M.L.; Stroehlein, J.R. Outcome of EMR as an alternative to surgery in patients with complex colon polyps. Gastrointest. Endosc., 2016, 84(2), 315-325.
[http://dx.doi.org/10.1016/j.gie.2016.01.067] [PMID: 26859866]

Ma, B.; Gao, P.; Song, Y.; Zhang, C.; Zhang, C.; Wang, L.; Liu, H.; Wang, Z. Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision. BMC Cancer, 2016, 16(1), 380.
[http://dx.doi.org/10.1186/s12885-016-2428-5] [PMID: 27377924]

Ricciardiello, L.; Bazzoli, F.; Fogliano, V. Phytochemicals and colorectal cancer prevention--myth or reality? Nat. Rev. Gastroenterol. Hepatol., 2011, 8(10), 592-596.
[http://dx.doi.org/10.1038/nrgastro.2011.149] [PMID: 21894197]

Bevacizumab - National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab (Accessed date: March 17, 2020).

Rosen, L.S.; Jacobs, I.A.; Burkes, R.L. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target. Oncol., 2017, 12(5), 599-610.
[http://dx.doi.org/10.1007/s11523-017-0518-1] [PMID: 28801849]

Hasan, M.R.; Ho, S.H.; Owen, D.A.; Tai, I.T. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int. J. Cancer, 2011, 129(9), 2115-2123.
[http://dx.doi.org/10.1002/ijc.26179] [PMID: 21618508]

Irinotecan hydrochloride. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/irinotecanhydrochloride (Accessed date: March 17, 2020).

Pommier, Y. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol., 2013, 8(1), 82-95.
[http://dx.doi.org/10.1021/cb300648v] [PMID: 23259582]

Capecitabine. Available at: https://www.cancer.gov/about- cancer/treatment/drugs/capecitabine (Accessed date: March 17, 2020).

Comella, P. A review of the role of capecitabine in the treatment of colorectal cancer. Ther. Clin. Risk Manag., 2007, 3(3), 421-431.

Cetuximab. Available at: https://www.cancer.gov/about- cancer/treatment/drugs/cetuximab (Accessed date: March 17, 2020).

Zhao, B.; Wang, L.; Qiu, H.; Zhang, M.; Sun, L.; Peng, P.; Yu, Q.; Yuan, X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget, 2017, 8(3), 3980-4000.
[http://dx.doi.org/10.18632/oncotarget.14012] [PMID: 28002810]

Ramucirumab. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/ramucirumab (Accessed date: March 17, 2020).

Xie, Y-H.; Chen, Y-X.; Fang, J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther., 2020, 5(1), 22.
[http://dx.doi.org/10.1038/s41392-020-0116-z] [PMID: 32296018]

Oxaliplatin. Available at: https://www.cancer.gov/about- cancer/treatment/drugs/oxaliplatin (Accessed date: March 17, 2020).

Alcindor, T.; Beauger, N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr. Oncol., 2011, 18(1), 18-25.
[http://dx.doi.org/10.3747/co.v18i1.708] [PMID: 21331278]

Fluorouracil Injection. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/fluorouracil (Accessed date: 10th September 2020).

Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338.
[http://dx.doi.org/10.1038/nrc1074] [PMID: 12724731]

Ipilimumab. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab (Accessed date: 10th September 2020).

Yaghoubi, N.; Soltani, A.; Ghazvini, K.; Hassanian, S.M.; Hashemy, S.I. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed. Pharmacother., 2019, 110, 312-318.
[http://dx.doi.org/10.1016/j.biopha.2018.11.105] [PMID: 30522017]

Pembrolizumab. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab (Accessed date: 10th September 2020).

Leucovorincalcium. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/leucovorincalcium (Accessed date: 10th September 2020).

Wang, S.; Wang, L.; Zhou, Z.; Deng, Q.; Li, L.; Zhang, M.; Liu, L.; Li, Y. Leucovorin enhances the anti-cancer effect of bortezomib in colorectal cancer cells. Sci. Rep., 2017, 7(1), 682.
[http://dx.doi.org/10.1038/s41598-017-00839-9] [PMID: 28386133]

Trifluridine and Tipiracil Hydrochloride. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/trifluridine-tipiracilhydrochloride (Accessed date: 10th September 2020).

Chen, J.; Han, M.; Saif, M.W. TAS-102 an emerging oral fluoropyrimidine. Anticancer Res., 2016, 36(1), 21-26.
[PMID: 26722024]

Nivolumab. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab (Accessed date: 10th September 2020).

Jácome, A.A.; Eng, C. Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opin. Biol. Ther., 2019, 19(12), 1247-1263.
[http://dx.doi.org/10.1080/14712598.2019.1680636] [PMID: 31642347]

Panitumumab. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/panitumumab (Accessed date: 10th September 2020).

Regorafenib. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/regorafenib (Accessed date: 10th September 2020).

Grothey, A.; Prager, G.; Yoshino, T. The mechanism of action of regorafenib in colorectal cancer: a guide for the community physician. Clin. Adv. Hematol. Oncol., 2019, 17(8)(Suppl. 12), 1-19.
[PMID: 32720931]

Ziv-Aflibercept. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/ziv-aflibercept (Accessed date: 10th September 2020).

Patel, A.; Sun, W. Ziv-aflibercept in metastatic colorectal cancer. Biol. Targets Ther., 2014, 8, 13-25.
[http://dx.doi.org/10.2147/BTT.S39360] [PMID: 24368879]

Palozza, P.; Serini, S.; Maggiano, N.; Tringali, G.; Navarra, P.; Ranelletti, F.O.; Calviello, G. β-Carotene downregulates the steady-state and heregulin-α-induced COX-2 pathways in colon cancer cells. J. Nutr., 2005, 135(1), 129-136.
[http://dx.doi.org/10.1093/jn/135.1.129] [PMID: 15623844]

Choi, S-Y.; Park, J.H.Y.; Kim, J-S.; Kim, M.K.; Aruoma, O.I.; Sung, M-K. Effects of quercetin and β-carotene supplementation on azoxymethane-induced colon carcinogenesis and inflammatory responses in rats fed with high-fat diet rich in omega-6 fatty acids. Biofactors, 2006, 27(1-4), 137-146.
[http://dx.doi.org/10.1002/biof.5520270112] [PMID: 17012770]

Pham, D.N.T.; Leclerc, D.; Lévesque, N.; Deng, L.; Rozen, R. β,β-carotene 15,15′-monooxygenase and its substrate β-carotene modulate migration and invasion in colorectal carcinoma cells. Am. J. Clin. Nutr., 2013, 98(2), 413-422.
[http://dx.doi.org/10.3945/ajcn.113.060996] [PMID: 23803888]

Paolini, M.; Cantelli-Forti, G.; Perocco, P.; Pedulli, G.F.; Abdel-Rahman, S.Z.; Legator, M.S. Co-carcinogenic effect of β-carotene. Nature, 1999, 398(6730), 760-761.
[http://dx.doi.org/10.1038/19655] [PMID: 10235258]

Palozza, P.; Serini, S.; Torsello, A.; Di Nicuolo, F.; Piccioni, E.; Ubaldi, V.; Pioli, C.; Wolf, F.I.; Calviello, G. β- carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells. J. Nutr., 2003, 133(2), 381-388.
[http://dx.doi.org/10.1093/jn/133.2.381] [PMID: 12566471]

Nishino, H.; Tokuda, H.; Murakoshi, M.; Satomi, Y.; Masuda, M.; Onozuka, M.; Yamaguchi, S.; Takayasu, J.; Tsuruta, J.; Okuda, M.; Khachik, F.; Narisawa, T.; Takasuka, N.; Yano, M. Cancer prevention by natural carotenoids. Biofactors, 2000, 13(1-4), 89-94.
[http://dx.doi.org/10.1002/biof.5520130115] [PMID: 11237205]

Srinivasan, M.; Sudheer, A.R.; Pillai, K.R.; Kumar, P.R.; Sudhakaran, P.R.; Menon, V.P. Lycopene as a natural protector against γ-radiation induced DNA damage, lipid peroxidation and antioxidant status in primary culture of isolated rat hepatocytes in vitro. Biochim. Biophys. Acta, 2007, 1770(4), 659-665.
[http://dx.doi.org/10.1016/j.bbagen.2006.11.008] [PMID: 17189673]

Sengupta, A.; Ghosh, S.; Das, R.K.; Bhattacharjee, S.; Bhattacharya, S. Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways. Eur. J. Cancer Prev., 2006, 15(4), 301-305.
[http://dx.doi.org/10.1097/00008469-200608000-00005] [PMID: 16835502]

Tang, F-Y.; Shih, C-J.; Cheng, L-H.; Ho, H-J.; Chen, H-J. Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Mol. Nutr. Food Res., 2008, 52(6), 646-654.
[http://dx.doi.org/10.1002/mnfr.200700272] [PMID: 18537129]

Palozza, P.; Colangelo, M.; Simone, R.; Catalano, A.; Boninsegna, A.; Lanza, P.; Monego, G.; Ranelletti, F.O. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis, 2010, 31(10), 1813-1821.
[http://dx.doi.org/10.1093/carcin/bgq157] [PMID: 20699249]

Tang, F-Y.; Pai, M-H.; Wang, X-D. Consumption of lycopene inhibits the growth and progression of colon cancer in a mouse xenograft model. J. Agric. Food Chem., 2011, 59(16), 9011-9021.
[http://dx.doi.org/10.1021/jf2017644] [PMID: 21744871]

Murakami, A.; Ashida, H.; Terao, J. Multitargeted cancer prevention by quercetin. Cancer Lett., 2008, 269(2), 315-325.
[http://dx.doi.org/10.1016/j.canlet.2008.03.046] [PMID: 18467024]

Mutoh, M.; Takahashi, M.; Fukuda, K.; Komatsu, H.; Enya, T.; Matsushima-Hibiya, Y.; Mutoh, H.; Sugimura, T.; Wakabayashi, K. Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells: structure-activity relationship. Jpn. J. Cancer Res., 2000, 91(7), 686-691.
[http://dx.doi.org/10.1111/j.1349-7006.2000.tb01000.x] [PMID: 10920275]

Zhang, X-A.; Zhang, S.; Yin, Q.; Zhang, J. Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B Pathway. Pharmacogn. Mag., 2015, 11(42), 404-409.
[http://dx.doi.org/10.4103/0973-1296.153096] [PMID: 25829782]

Priego, S.; Feddi, F.; Ferrer, P.; Mena, S.; Benlloch, M.; Ortega, A.; Carretero, J.; Obrador, E.; Asensi, M.; Estrela, J.M. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Mol. Cancer Ther., 2008, 7(10), 3330-3342.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0363] [PMID: 18852136]

Park, C.H.; Chang, J.Y.; Hahm, E.R.; Park, S.; Kim, H-K.; Yang, C.H. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun., 2005, 328(1), 227-234.
[http://dx.doi.org/10.1016/j.bbrc.2004.12.151] [PMID: 15670774]

Shan, B-E.; Wang, M-X.; Li, R.Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/β- catenin signaling pathway. Cancer Invest., 2009, 27(6), 604-612.
[http://dx.doi.org/10.1080/07357900802337191] [PMID: 19440933]

Kim, H-J.; Kim, S-K.; Kim, B-S.; Lee, S-H.; Park, Y-S.; Park, B-K.; Kim, S-J.; Kim, J.; Choi, C.; Kim, J-S.; Cho, S.D.; Jung, J.W.; Roh, K.H.; Kang, K.S.; Jung, J.Y. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J. Agric. Food Chem., 2010, 58(15), 8643-8650.
[http://dx.doi.org/10.1021/jf101510z] [PMID: 20681654]

Chisté, R.C.; Freitas, M.; Mercadante, A.Z.; Fernandes, E. Carotenoids are effective inhibitors of in vitro hemolysis of human erythrocytes, as determined by a practical and optimized cellular antioxidant assay. J. Food Sci., 2014, 79(9), H1841-H1847.
[http://dx.doi.org/10.1111/1750-3841.12580] [PMID: 25141990]

Grudzinski, W.; Piet, M.; Luchowski, R.; Reszczynska, E.; Welc, R.; Paduch, R.; Gruszecki, W.I. Different molecular organization of two carotenoids, lutein and zeaxanthin, in human colon epithelial cells and colon adenocarcinoma cells. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2018, 188, 57-63.
[http://dx.doi.org/10.1016/j.saa.2017.06.041] [PMID: 28689079]

Zhao, Y.; Hu, X.; Zuo, X.; Wang, M. Chemopreventive effects of some popular phytochemicals on human colon cancer: a review. Food Funct., 2018, 9(9), 4548-4568.
[http://dx.doi.org/10.1039/C8FO00850G] [PMID: 30118121]

Sung, B.; Chung, H.Y.; Kim, N.D. Role of apigenin in cancer prevention via the induction of apoptosis and autophagy. J. Cancer Prev., 2016, 21(4), 216-226.
[http://dx.doi.org/10.15430/JCP.2016.21.4.216] [PMID: 28053955]

Madunić, J.; Madunić, I.V.; Gajski, G.; Popić, J.; Garaj-Vrhovac, V. Apigenin: A dietary flavonoid with diverse anticancer properties. Cancer Lett., 2018, 413, 11-22.
[http://dx.doi.org/10.1016/j.canlet.2017.10.041] [PMID: 29097249]

Karthik Kumar, V.; Vennila, S.; Nalini, N. Inhibitory effect of morin on DMH-induced biochemical changes and aberrant crypt foci formation in experimental colon carcinogenesis. Environ. Toxicol. Pharmacol., 2010, 29(1), 50-57.
[http://dx.doi.org/10.1016/j.etap.2009.09.006] [PMID: 21787582]

Sharma, S.H.; Thulasingam, S.; Chellappan, D.R.; Chinnaswamy, P.; Nagarajan, S. Morin and Esculetin supplementation modulates c-myc induced energy metabolism and attenuates neoplastic changes in rats challenged with the procarcinogen 1,2 - dimethylhydrazine. Eur. J. Pharmacol., 2017, 796, 20-31.
[http://dx.doi.org/10.1016/j.ejphar.2016.12.019] [PMID: 27989504]

Gálvez, J.; Coelho, G.; Crespo, M.E.; Cruz, T.; Rodríguez- Cabezas, M.E.; Concha, A.; Gonzalez, M.; Zarzuelo, A. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Aliment. Pharmacol. Ther., 2001, 15(12), 2027-2039.
[http://dx.doi.org/10.1046/j.1365-2036.2001.01133.x] [PMID: 11736735]

Sharma, S.H.; Kumar, J.S.; Chellappan, D.R.; Nagarajan, S. Molecular chemoprevention by morin - a plant flavonoid that targets nuclear factor kappa B in experimental colon cancer. Biomed. Pharmacother., 2018, 100, 367-373.
[http://dx.doi.org/10.1016/j.biopha.2018.02.035] [PMID: 29453046]

Hyun, H-B.; Lee, W.S.; Go, S-I.; Nagappan, A.; Park, C.; Han, M.H.; Hong, S.H.; Kim, G.; Kim, G.Y.; Cheong, J.; Ryu, C.H.; Shin, S.C.; Choi, Y.H. The flavonoid morin from Moraceae induces apoptosis by modulation of Bcl-2 family members and Fas receptor in HCT 116 cells. Int. J. Oncol., 2015, 46(6), 2670-2678.
[http://dx.doi.org/10.3892/ijo.2015.2967] [PMID: 25892545]

Kim, J-M.; Kim, J-S.; Yoo, H.; Choung, M-G.; Sung, M-K. Effects of black soybean [Glycine max (L.) Merr.] seed coats and its anthocyanidins on colonic inflammation and cell proliferation in vitro and in vivo. J. Agric. Food Chem., 2008, 56(18), 8427-8433.
[http://dx.doi.org/10.1021/jf801342p] [PMID: 18710248]

Cvorovic, J.; Tramer, F.; Granzotto, M.; Candussio, L.; Decorti, G.; Passamonti, S. Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells. Arch. Biochem. Biophys., 2010, 501(1), 151-157.
[http://dx.doi.org/10.1016/j.abb.2010.05.019] [PMID: 20494645]

Yun, J-M.; Afaq, F.; Khan, N.; Mukhtar, H. Delphinidin, an anthocyanidin in pigmented fruits and vegetables, induces apoptosis and cell cycle arrest in human colon cancer HCT116 cells. Mol. Carcinog., 2009, 48(3), 260-270.
[http://dx.doi.org/10.1002/mc.20477] [PMID: 18729103]

Song, H.M.; Park, G.H.; Eo, H.J.; Jeong, J.B. Naringenin- mediated ATF3 expression contributes to apoptosis in human colon cancer. Biomol. Ther. (Seoul), 2016, 24(2), 140-146.
[http://dx.doi.org/10.4062/biomolther.2015.109] [PMID: 26797111]

Araújo, J.R.; Gonçalves, P.; Martel, F. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr. Res., 2011, 31(2), 77-87.
[http://dx.doi.org/10.1016/j.nutres.2011.01.006] [PMID: 21419311]

Lambert, J.D.; Yang, C.S. Mechanisms of cancer prevention by tea constituents. J. Nutr., 2003, 133(10), 3262S-3267S.
[http://dx.doi.org/10.1093/jn/133.10.3262S] [PMID: 14519824]

Khan, N.; Afaq, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res., 2006, 66(5), 2500-2505.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3636] [PMID: 16510563]

Forester, S.C.; Choy, Y.Y.; Waterhouse, A.L.; Oteiza, P.I. The anthocyanin metabolites gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde decrease human colon cancer cell viability by regulating pro-oncogenic signals. Mol. Carcinog., 2014, 53(6), 432-439.
[http://dx.doi.org/10.1002/mc.21974] [PMID: 23124926]

López de Las Hazas, M-C.; Mosele, J.I.; Macià, A.; Ludwig, I.A.; Motilva, M-J. Exploring the colonic metabolism of grape and strawberry anthocyanins and their in vitro apoptotic effects in HT-29 colon cancer cells. J. Agric. Food Chem., 2017, 65(31), 6477-6487.
[http://dx.doi.org/10.1021/acs.jafc.6b04096] [PMID: 27790915]

Sun, G.; Zheng, Z.; Lee, M-H.; Xu, Y.; Kang, S.; Dong, Z.; Wang, M.; Gu, Z.; Li, H.; Chen, W. Chemoprevention of colorectal cancer by artocarpin, a dietary phytochemical from Artocarpus heterophyllus. J. Agric. Food Chem., 2017, 65(17), 3474-3480.
[http://dx.doi.org/10.1021/acs.jafc.7b00278] [PMID: 28391699]

Raina, K.; Kumar, S.; Dhar, D.; Agarwal, R. Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J. Biomed. Res., 2016, 30(6), 452-465.
[http://dx.doi.org/10.7555/JBR.30.20150111] [PMID: 27476880]

Amado, N.G.; Predes, D.; Moreno, M.M.; Carvalho, I.O.; Mendes, F.A.; Abreu, J.G. Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies. Int. J. Mol. Sci., 2014, 15(7), 12094-12106.
[http://dx.doi.org/10.3390/ijms150712094] [PMID: 25007066]

Raina, K.; Agarwal, C.; Agarwal, R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol. Carcinog., 2013, 52(3), 195-206.
[http://dx.doi.org/10.1002/mc.21843] [PMID: 22086675]

Luo, Y.; Wang, S.X.; Zhou, Z.Q.; Wang, Z.; Zhang, Y.G.; Zhang, Y.; Zhao, P. Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-kappa B (NF-κB) pathway. Tumour Biol., 2014, 35(11), 11483-11488.
[http://dx.doi.org/10.1007/s13277-014-2487-7] [PMID: 25128065]

Liang, Y-S.; Qi, W-T.; Guo, W.; Wang, C-L.; Hu, Z-B.; Li, A-K. Genistein and daidzein induce apoptosis of colon cancer cells by inhibiting the accumulation of lipid droplets. Food Nutr. Res., 2018, 62
[http://dx.doi.org/10.29219/fnr.v62.1384] [PMID: 29849534]

González-Mauraza, H.; Martín-Cordero, C.; Alarcón-de-la-Lastra, C.; Rosillo, M.A.; León-González, A.J.; Sánchez-Hidalgo, M. Anti-inflammatory effects of Retama monosperma in acute ulcerative colitis in rats. J. Physiol. Biochem., 2014, 70(1), 163-172.
[http://dx.doi.org/10.1007/s13105-013-0290-3] [PMID: 24057513]

Pintova, S.; Planutis, K.; Planutiene, M.; Holcombe, R.F. ME-143 is superior to genistein in suppression of WNT signaling in colon cancer cells. Anticancer Res., 2017, 37(4), 1647-1653.
[http://dx.doi.org/10.21873/anticanres.11495] [PMID: 28373425]

Kawamori, T.; Lubet, R.; Steele, V.E.; Kelloff, G.J.; Kaskey, R.B.; Rao, C.V.; Reddy, B.S. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res., 1999, 59(3), 597-601.

Johnson, J.J.; Mukhtar, H. Curcumin for chemoprevention of colon cancer. Cancer Lett., 2007, 255(2), 170-181.
[http://dx.doi.org/10.1016/j.canlet.2007.03.005] [PMID: 17448598]

Goel, A.; Boland, C.R.; Chauhan, D.P. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett., 2001, 172(2), 111-118.
[http://dx.doi.org/10.1016/S0304-3835(01)00655-3] [PMID: 11566484]

Moragoda, L.; Jaszewski, R.; Majumdar, A.P. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res., 2001, 21(2A), 873-878.
[PMID: 11396178]

Juan, M.E.; Alfaras, I.; Planas, J.M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol. Res., 2012, 65(6), 584-591.
[http://dx.doi.org/10.1016/j.phrs.2012.03.010] [PMID: 22465196]

Vanamala, J.; Reddivari, L.; Radhakrishnan, S.; Tarver, C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer, 2010, 10(1), 238.
[http://dx.doi.org/10.1186/1471-2407-10-238] [PMID: 20504360]

Khanzadeh, T.; Hagh, M.F.; Talebi, M.; Yousefi, B.; Azimi, A.; Hossein Pour Feizi, A.A.; Baradaran, B. Investigation of BAX and BCL2 expression and apoptosis in a resveratrol- and prednisolone-treated human T-ALL cell line, CCRF-CEM. Blood Res., 2018, 53(1), 53-60.
[http://dx.doi.org/10.5045/br.2018.53.1.53] [PMID: 29662863]

Chen, H-J.; Hsu, L-S.; Shia, Y-T.; Lin, M-W.; Lin, C-M. The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem. Pharmacol., 2012, 84(9), 1143-1153.
[http://dx.doi.org/10.1016/j.bcp.2012.08.011] [PMID: 22935447]

Ji, Q.; Liu, X.; Fu, X.; Zhang, L.; Sui, H.; Zhou, L.; Sun, J.; Cai, J.; Qin, J.; Ren, J.; Li, Q. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One, 2013, 8(11), e78700.
[http://dx.doi.org/10.1371/journal.pone.0078700] [PMID: 24244343]

Sánchez-Fidalgo, S.; Cárdeno, A.; Villegas, I.; Talero, E.; de la Lastra, C.A. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur. J. Pharmacol., 2010, 633(1-3), 78-84.
[http://dx.doi.org/10.1016/j.ejphar.2010.01.025] [PMID: 20132809]

Singletary, K.W.; Meline, B. Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr. Cancer, 2001, 39(2), 252-258.
[http://dx.doi.org/10.1207/S15327914nc392_15] [PMID: 11759289]

Engelbrecht, A-M.; Mattheyse, M.; Ellis, B.; Loos, B.; Thomas, M.; Smith, R.; Peters, S.; Smith, C.; Myburgh, K. Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Lett., 2007, 258(1), 144-153.
[http://dx.doi.org/10.1016/j.canlet.2007.08.020] [PMID: 17923279]

Huang, S.; Yang, N.; Liu, Y.; Gao, J.; Huang, T.; Hu, L.; Zhao, J.; Li, Y.; Li, C.; Zhang, X. Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1. Int. J. Mol. Med., 2012, 30(6), 1410-1416.
[http://dx.doi.org/10.3892/ijmm.2012.1147] [PMID: 23026853]

Umesalma, S.; Nagendraprabhu, P.; Sudhandiran, G. Antiproliferative and apoptotic-inducing potential of ellagic acid against 1,2-dimethyl hydrazine-induced colon tumorigenesis in Wistar rats. Mol. Cell. Biochem., 2014, 388(1-2), 157-172.
[http://dx.doi.org/10.1007/s11010-013-1907-0] [PMID: 24281858]

Umesalma, S.; Nagendraprabhu, P.; Sudhandiran, G. Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells. Mol. Cell. Biochem., 2015, 399(1-2), 303-313.
[http://dx.doi.org/10.1007/s11010-014-2257-2] [PMID: 25355159]

Ramírez de Molina, A.; Vargas, T.; Molina, S.; Sánchez, J.; Martínez-Romero, J.; González-Vallinas, M.; Martín-Hernández, R.; Sánchez-Martínez, R.; Gómez de Cedrón, M.; Dávalos, A.; Calani, L.; Del Rio, D.; González-Sarrías, A.; Espín, J.C.; Tomás-Barberán, F.A.; Reglero, G. The ellagic acid derivative 4,4′-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16. J. Pharmacol. Exp. Ther., 2015, 353(2), 433-444.
[http://dx.doi.org/10.1124/jpet.114.221796] [PMID: 25758919]

Cheung, K.L.; Khor, T.O.; Huang, M-T.; Kong, A-N. Cancer chemoprevention of azoxymethane/dextran sodium sulfate-induced colon carcinogenesis by phenethyl isothiocyanate and dibenzoylmethane. Carcinogenesis, 2009, 31(5), 880-885.
[http://dx.doi.org/10.1093/carcin/bgp285] [PMID: 19959557]

Li, H.; Fan, Y.; Zhang, L.; Liu, A.; Tu, F.; He, K.; Zhang, J. Phenethyl isothiocyanate inhibits the migration and invasion of colon cancer SW480 cells via the inhibition of matrix metalloproteinase-9. Int. J. Clin. Exp. Med., 2016, 9(2), 2423-2429.

Parnaud, G.; Li, P.; Cassar, G.; Rouimi, P.; Tulliez, J.; Combaret, L.; Gamet-Payrastre, L. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr. Cancer, 2004, 48(2), 198-206.
[http://dx.doi.org/10.1207/s15327914nc4802_10] [PMID: 15231455]

Cheung, K.L.; Kong, A-N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J., 2010, 12(1), 87-97.
[http://dx.doi.org/10.1208/s12248-009-9162-8] [PMID: 20013083]

Rajendran, P.; Delage, B.; Dashwood, W.M.; Yu, T-W.; Wuth, B.; Williams, D.E.; Ho, E.; Dashwood, R.H. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol. Cancer, 2011, 10(1), 68.
[http://dx.doi.org/10.1186/1476-4598-10-68] [PMID: 21624135]

Kim, D.H.; Sung, B.; Kang, Y.J.; Hwang, S.Y.; Kim, M.J.; Yoon, J-H. Im, E.; Kim, N.D. Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells. Int. J. Oncol., 2015, 47(6), 2226-2232.
[http://dx.doi.org/10.3892/ijo.2015.3200] [PMID: 26498863]

Martin, S.L.; Kala, R.; Tollefsbol, T.O. Mechanisms for the inhibition of colon cancer cells by sulforaphane through epigenetic modulation of MicroRNA-21 and human telomerase reverse transcriptase (hTERT) down-regulation. Curr. Cancer Drug Targets, 2018, 18(1), 97-106.
[http://dx.doi.org/10.2174/1568009617666170206104032] [PMID: 28176652 ]

Abe, N.; Hou, D.X.; Munemasa, S.; Murata, Y.; Nakamura, Y. Nuclear factor-kappaB sensitizes to benzyl isothiocyanate-induced antiproliferation in p53-deficient colorectal cancer cells. Cell Death Dis., 2014, 5(11), e1534-e1534.
[http://dx.doi.org/10.1038/cddis.2014.495] [PMID: 25412312]

Jia, S-S.; Xi, G-P.; Zhang, M.; Chen, Y-B.; Lei, B.; Dong, X-S.; Yang, Y-M. Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells. Oncol. Rep., 2013, 29(1), 349-354.
[http://dx.doi.org/10.3892/or.2012.2093] [PMID: 23117412]

Kawamori, T.; Tanaka, T.; Hirose, Y.; Ohnishi, M.; Mori, H. Inhibitory effects of d-limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Carcinogenesis, 1996, 17(2), 369-372.
[http://dx.doi.org/10.1093/carcin/17.2.369] [PMID: 8625465]

Reddy, B.S.; Wang, C.X.; Samaha, H.; Lubet, R.; Steele, V.E.; Kelloff, G.J.; Rao, C.V. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res., 1997, 57(3), 420-425.
[PMID: 9012468]

Belanger, J.T. Perillyl alcohol: applications in oncology. Altern. Med. Rev., 1998, 3(6), 448-457.
[PMID: 9855569]

Kim, M.; Miyamoto, S.; Yasui, Y.; Oyama, T.; Murakami, A.; Tanaka, T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int. J. Cancer, 2009, 124(2), 264-271.
[http://dx.doi.org/10.1002/ijc.23923] [PMID: 19003968]

Huang, X.; Awano, Y.; Maeda, E.; Asada, Y.; Takemoto, H.; Watanabe, T.; Kojima-Yuasa, A.; Kobayashi, Y. Cytotoxic activity of two natural sesquiterpene lactones, isobutyroylplenolin and arnicolide D, on human colon cancer cell line HT-29. Nat. Prod. Res., 2014, 28(12), 914-916.
[http://dx.doi.org/10.1080/14786419.2014.889133] [PMID: 24588282]

Fan, K.; Li, X.; Cao, Y.; Qi, H.; Li, L.; Zhang, Q.; Sun, H. Carvacrol inhibits proliferation and induces apoptosis in human colon cancer cells. Anticancer Drugs, 2015, 26(8), 813-823.
[http://dx.doi.org/10.1097/CAD.0000000000000263] [PMID: 26214321]

Arigesavan, K.; Sudhandiran, G. Carvacrol exhibits anti-oxidant and anti-inflammatory effects against 1, 2-dimethyl hydrazine plus dextran sodium sulfate induced inflammation associated carcinogenicity in the colon of Fischer 344 rats. Biochem. Biophys. Res. Commun., 2015, 461(2), 314-320.
[http://dx.doi.org/10.1016/j.bbrc.2015.04.030] [PMID: 25881504]

Shi, M-D.; Lin, H-H.; Lee, Y-C.; Chao, J-K.; Lin, R-A.; Chen, J-H. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem. Biol. Interact., 2008, 174(3), 201-210.
[http://dx.doi.org/10.1016/j.cbi.2008.06.006] [PMID: 18619950]

Chao, H-P.; Kuo, C-D.; Chiu, J-H.; Fu, S-L. Andrographolide exhibits anti-invasive activity against colon cancer cells via inhibition of MMP2 activity. Planta Med., 2010, 76(16), 1827-1833.
[http://dx.doi.org/10.1055/s-0030-1250039] [PMID: 20539971]

Banerjee, A.; Ahmed, H.; Yang, P.; Czinn, S.J.; Blanchard, T.G. Endoplasmic reticulum stress and IRE-1 signaling cause apoptosis in colon cancer cells in response to andrographolide treatment. Oncotarget, 2016, 7(27), 41432-41444.
[http://dx.doi.org/10.18632/oncotarget.9180] [PMID: 27166181]

Rzeski, W.; Stepulak, A.; Szymański, M.; Sifringer, M.; Kaczor, J.; Wejksza, K.; Zdzisińska, B.; Kandefer-Szerszeń, M. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 374(1), 11-20.
[http://dx.doi.org/10.1007/s00210-006-0090-1] [PMID: 16964520]

Chintharlapalli, S.; Papineni, S.; Lei, P.; Pathi, S.; Safe, S. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 2011, 11(1), 371.
[http://dx.doi.org/10.1186/1471-2407-11-371] [PMID: 21864401]

Zhang, J.; Wang, Y.; Zhou, Y.; He, Q-Y.; Jolkinolide, B. Jolkinolide B induces apoptosis of colorectal carcinoma through ROS-ER stress-Ca²⁺-mitochondria dependent pathway. Oncotarget, 2017, 8(53), 91223-91237.
[http://dx.doi.org/10.18632/oncotarget.20077] [PMID: 29207638]

Johnson, J.J. Carnosol: a promising anti-cancer and anti-inflammatory agent. Cancer Lett., 2011, 305(1), 1-7.
[http://dx.doi.org/10.1016/j.canlet.2011.02.005] [PMID: 21382660]

Park, K-W.; Kundu, J.; Chae, I-G.; Kim, D-H.; Yu, M-H.; Kundu, J.K.; Chun, K-S. Carnosol induces apoptosis through generation of ROS and inactivation of STAT₃ signaling in human colon cancer HCT116 cells. Int. J. Oncol., 2014, 44(4), 1309-1315.
[http://dx.doi.org/10.3892/ijo.2014.2281] [PMID: 24481553]

Thakur, R.; Mishra, D.P. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J. Cell. Mol. Med., 2013, 17(4), 449-456.
[http://dx.doi.org/10.1111/jcmm.12033] [PMID: 23490077]

Li, S.; Cheng, B.; Hou, L.; Huang, L.; Cui, Y.; Xu, D.; Shen, X.; Li, S. Dioscin inhibits colon cancer cells’ growth by reactive oxygen species-mediated mitochondrial dysfunction and p38 and JNK pathways. Anticancer Drugs, 2018, 29(3), 234-242.
[http://dx.doi.org/10.1097/CAD.0000000000000590] [PMID: 29389802]

Chen, H.; Xu, L.; Yin, L.; Xu, Y.; Han, X.; Qi, Y.; Zhao, Y.; Liu, K.; Peng, J. iTRAQ-based proteomic analysis of dioscin on human HCT-116 colon cancer cells. Proteomics, 2014, 14(1), 51-73.
[http://dx.doi.org/10.1002/pmic.201300101] [PMID: 24420967]

Ma, B.; Gao, P.; Wang, H.; Xu, Q.; Song, Y.; Huang, X.; Sun, J.; Zhao, J.; Luo, J.; Sun, Y.; Wang, Z. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int. J. Cancer, 2017, 141(5), 1052-1065.
[http://dx.doi.org/10.1002/ijc.30805] [PMID: 28560805]

Du, D.; Su, Z.; Wang, D.; Liu, W.; Wei, Z. Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin. Colorectal Cancer, 2018, 17(1), 13-24.
[http://dx.doi.org/10.1016/j.clcc.2017.10.012] [PMID: 29153429]

Ryan, J.E.; Warrier, S.K.; Lynch, A.C.; Ramsay, R.G.; Phillips, W.A.; Heriot, A.G. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis., 2016, 18(3), 234-246.
[http://dx.doi.org/10.1111/codi.13207] [PMID: 26531759]

Abdel-Rahman, O.; Cheung, W.Y. Integrating systemic therapies into the multimodality treatment of resectable colorectal liver metastases. Gastroenterol. Res. Pract., 2018, 2018, 4326082.
[http://dx.doi.org/10.1155/2018/4326082 ] [PMID: 30034465]

Baratti, D.; Kusamura, S.; Pietrantonio, F.; Guaglio, M.; Niger, M.; Deraco, M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. Crit. Rev. Oncol. Hematol., 2016, 100, 209-222.
[http://dx.doi.org/10.1016/j.critrevonc.2016.01.017] [PMID: 26867984]

Colorectal cancer types. Cancer treatment centers of America. Available at: https://www.cancercenter.com/cancer- types/colorectal-cancer/types (Accessed date: 10th September 2020).

What is colorectal cancer? American Cancer Society. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/about/what-is-colorectal-cancer.html (Accessed date: 10th September 2020).

van der Geest, L.G.; Lam-Boer, J.; Koopman, M.; Verhoef, C.; Elferink, M.A.; de Wilt, J.H. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin. Exp. Metastasis, 2015, 32(5), 457-465.
[http://dx.doi.org/10.1007/s10585-015-9719-0] [PMID: 25899064]

Riihimäki, M.; Hemminki, A.; Sundquist, J.; Hemminki, K. Patterns of metastasis in colon and rectal cancer. Sci. Rep., 2016, 6(1), 29765.
[http://dx.doi.org/10.1038/srep29765] [PMID: 27416752]

Cook, A.D.; Single, R.; McCahill, L.E. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann. Surg. Oncol., 2005, 12(8), 637-645.
[http://dx.doi.org/10.1245/ASO.2005.06.012] [PMID: 15965730]

Desch, C.E.; Benson, A.B., III; Somerfield, M.R.; Flynn, P.J.; Krause, C.; Loprinzi, C.L.; Minsky, B.D.; Pfister, D.G.; Virgo, K.S.; Petrelli, N.J. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol., 2005, 23(33), 8512-8519.
[http://dx.doi.org/10.1200/JCO.2005.04.0063] [PMID: 16260687]

Pretzsch, E.; Bösch, F.; Neumann, J.; Ganschow, P.; Bazhin, A.; Guba, M.; Werner, J.; Angele, M. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J. Oncol., 2019, 2019, 7407190.
[http://dx.doi.org/10.1155/2019/7407190] [PMID: 31641356]

Segelman, J.; Granath, F.; Holm, T.; Machado, M.; Mahteme, H.; Martling, A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg., 2012, 99(5), 699-705.
[http://dx.doi.org/10.1002/bjs.8679] [PMID: 22287157]

van Gestel, Y.R.; Thomassen, I.; Lemmens, V.E.; Pruijt, J.F.; van Herk-Sukel, M.P.; Rutten, H.J.; Creemers, G-J.; de Hingh, I.H. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur. J. Surg. Oncol., 2014, 40(8), 963-969.
[http://dx.doi.org/10.1016/j.ejso.2013.10.001] [PMID: 24183168]

Thomassen, I.; van Gestel, Y.R.; Lemmens, V.E.; de Hingh, I.H. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis. Colon Rectum, 2013, 56(12), 1373-1380.
[http://dx.doi.org/10.1097/DCR.0b013e3182a62d9d] [PMID: 24201391]

Cao, H.; Xu, E.; Liu, H.; Wan, L.; Lai, M. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol. Res. Pract., 2015, 211(8), 557-569.
[http://dx.doi.org/10.1016/j.prp.2015.05.010] [PMID: 26092594]

Sluiter, N.; de Cuba, E.; Kwakman, R.; Kazemier, G.; Meijer, G.; Te Velde, E.A. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin. Exp. Metastasis, 2016, 33(5), 401-416.
[http://dx.doi.org/10.1007/s10585-016-9791-0] [PMID: 27074785]

Marcuello, M.; Mayol, X.; Felipe-Fumero, E.; Costa, J.; López-Hierro, L.; Salvans, S.; Alonso, S.; Pascual, M.; Grande, L.; Pera, M. Modulation of the colon cancer cell phenotype by pro-inflammatory macrophages: a preclinical model of surgery-associated inflammation and tumor recurrence. PLoS One, 2018, 13(2), e0192958.
[http://dx.doi.org/10.1371/journal.pone.0192958] [PMID: 29462209]

de Cuba, E.M.V.; Kwakman, R.; van Egmond, M.; Bosch, L.J.W.; Bonjer, H.J.; Meijer, G.A.; te Velde, E.A. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch., 2012, 461(3), 231-243.
[http://dx.doi.org/10.1007/s00428-012-1287-y] [PMID: 22825001]

Medema, J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol., 2013, 15(4), 338-344.
[http://dx.doi.org/10.1038/ncb2717] [PMID: 23548926]

Nassar, D.; Blanpain, C. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol., 2016, 11(1), 47-76.
[http://dx.doi.org/10.1146/annurev-pathol-012615-044438] [PMID: 27193450]

de Sousa e Melo, F.; Kurtova, A.V.; Harnoss, J.M.; Kljavin, N.; Hoeck, J.D.; Hung, J.; Anderson, J.E.; Storm, E.E.; Modrusan, Z.; Koeppen, H.; Dijkgraaf, G.J.; Piskol, R.; de Sauvage, F.J. A distinct role for Lgr5⁺ stem cells in primary and metastatic colon cancer. Nature, 2017, 543(7647), 676-680.
[http://dx.doi.org/10.1038/nature21713] [PMID: 28358093]

Shimokawa, M.; Ohta, Y.; Nishikori, S.; Matano, M.; Takano, A.; Fujii, M.; Date, S.; Sugimoto, S.; Kanai, T.; Sato, T. Visualization and targeting of LGR5⁺ human colon cancer stem cells. Nature, 2017, 545(7653), 187-192.
[http://dx.doi.org/10.1038/nature22081] [PMID: 28355176]

Muzny, D.M.; Bainbridge, M.N.; Chang, K.; Dinh, H.H.; Drummond, J.A.; Fowler, G.; Kovar, C.L.; Lewis, L.R.; Morgan, M.B.; Newsham, I.F.; Reid, J.G.; Santibanez, J.; Shinbrot, E.; Trevino, L.R.; Wu, Y-Q.; Wang, M.; Gunaratne, P.; Donehower, L.A.; Creighton, C.J.; Wheeler, D.A.; Gibbs, R.A.; Lawrence, M.S.; Voet, D.; Jing, R.; Cibulskis, K.; Sivachenko, A.; Stojanov, P.; McKenna, A.; Lander, E.S.; Gabriel, S.; Getz, G.; Ding, L.; Fulton, R.S.; Koboldt, D.C.; Wylie, T.; Walker, J.; Dooling, D.J.; Fulton, L.; Delehaunty, K.D.; Fronick, C.C.; Demeter, R.; Mardis, E.R.; Wilson, R.K.; Chu, A.; Chun, H-J.E.; Mungall, A.J.; Pleasance, E.; Gordon Robertson, A.; Stoll, D.; Balasundaram, M.; Birol, I.; Butterfield, Y.S.N.; Chuah, E.; Coope, R.J.N.; Dhalla, N.; Guin, R.; Hirst, C.; Hirst, M.; Holt, R.A.; Lee, D.; Li, H.I.; Mayo, M.; Moore, R.A.; Schein, J.E.; Slobodan, J.R.; Tam, A.; Thiessen, N.; Varhol, R.; Zeng, T.; Zhao, Y.; Jones, S.J.M.; Marra, M.A.; Bass, A.J.; Ramos, A.H.; Saksena, G.; Cherniack, A.D.; Schumacher, S.E.; Tabak, B.; Carter, S.L.; Pho, N.H.; Nguyen, H.; Onofrio, R.C.; Crenshaw, A.; Ardlie, K.; Beroukhim, R.; Winckler, W.; Getz, G.; Meyerson, M.; Protopopov, A.; Zhang, J.; Hadjipanayis, A.; Lee, E.; Xi, R.; Yang, L.; Ren, X.; Zhang, H.; Sathiamoorthy, N.; Shukla, S.; Chen, P-C.; Haseley, P.; Xiao, Y.; Lee, S.; Seidman, J.; Chin, L.; Park, P.J.; Kucherlapati, R.; Todd Auman, J.; Hoadley, K.A.; Du, Y.; Wilkerson, M.D.; Shi, Y.; Liquori, C.; Meng, S.; Li, L.; Turman, Y.J.; Topal, M.D.; Tan, D.; Waring, S.; Buda, E.; Walsh, J.; Jones, C.D.; Mieczkowski, P.A.; Singh, D.; Wu, J.; Gulabani, A.; Dolina, P.; Bodenheimer, T.; Hoyle, A.P.; Simons, J.V.; Soloway, M.; Mose, L.E.; Jefferys, S.R.; Balu, S.; O’Connor, B.D.; Prins, J.F.; Chiang, D.Y.; Neil Hayes, D.; Perou, C.M.; Hinoue, T.; Weisenberger, D.J.; Maglinte, D.T.; Pan, F.; Berman, B.P.; Van Den Berg, D.J.; Shen, H.; Triche Jr, T.; Baylin, S.B.; Laird, P.W.; Getz, G.; Noble, M.; Voet, D.; Saksena, G.; Gehlenborg, N.; DiCara, D.; Zhang, J.; Zhang, H.; Wu, C-J.; Liu, Y.S.; Shukla, S.; Lawrence, M.S.; Zhou, L.; Sivachenko, A.; Lin, P.; Stojanov, P.; Jing, R.; Park, R.W.; Nazaire, M-D.; Robinson, J.; Thorvaldsdottir, H.; Mesirov, J.; Park, P.J.; Chin, L.; Thorsson, V.; Reynolds, S.M.; Bernard, B.; Kreisberg, R.; Lin, J.; Iype, L.; Bressler, R.; Erkkilä, T.; Gundapuneni, M.; Liu, Y.; Norberg, A.; Robinson, T.; Yang, D.; Zhang, W.; Shmulevich, I.; de Ronde, J.J.; Schultz, N.; Cerami, E.; Ciriello, G.; Goldberg, A.P.; Gross, B.; Jacobsen, A.; Gao, J.; Kaczkowski, B.; Sinha, R.; Arman Aksoy, B.; Antipin, Y.; Reva, B.; Shen, R.; Taylor, B.S.; Chan, T.A.; Ladanyi, M.; Sander, C.; Akbani, R.; Zhang, N.; Broom, B.M.; Casasent, T.; Unruh, A.; Wakefield, C.; Hamilton, S.R.; Craig Cason, R.; Baggerly, K.A.; Weinstein, J.N.; Haussler, D.; Benz, C.C.; Stuart, J.M.; Benz, S.C.; Zachary Sanborn, J.; Vaske, C.J.; Zhu, J.; Szeto, C.; Scott, G.K.; Yau, C.; Ng, S.; Goldstein, T.; Ellrott, K.; Collisson, E.; Cozen, A.E.; Zerbino, D.; Wilks, C.; Craft, B.; Spellman, P.; Penny, R.; Shelton, T.; Hatfield, M.; Morris, S.; Yena, P.; Shelton, C.; Sherman, M.; Paulauskis, J.; Gastier-Foster, J.M.; Bowen, J.; Ramirez, N.C.; Black, A.; Pyatt, R.; Wise, L.; White, P.; Bertagnolli, M.; Brown, J.; Chan, T.A.; Chu, G.C.; Czerwinski, C.; Denstman, F.; Dhir, R.; Dörner, A.; Fuchs, C.S.; Guillem, J.G.; Iacocca, M.; Juhl, H.; Kaufman, A.; Kohl, B., III; Van Le, X.; Mariano, M.C.; Medina, E.N.; Meyers, M.; Nash, G.M.; Paty, P.B.; Petrelli, N.; Rabeno, B.; Richards, W.G.; Solit, D.; Swanson, P.; Temple, L.; Tepper, J.E.; Thorp, R.; Vakiani, E.; Weiser, M.R.; Willis, J.E.; Witkin, G.; Zeng, Z.; Zinner, M.J. The Cancer Genome Atlas Network. Genome Sequencing Center Baylor College of Medicine; Genome Sequencing Center Broad Institute; Genome Sequencing Center Washington University in St Louis; Genome Characterization Center BC Cancer Agency; Genome-Characterization Center Broad Institute; Genome-Characterization Center Brigham and Women’s Hospital and Harvard Medical School; Genome-Characterization Center University of North Carolina, C. H.; Genome-Characterization Centers University of Southern California and Johns Hopkins University; Genome Data Analysis Center Broad Institute; Genome Data Analysis Center Institute for Systems Biology; Genome Data Analysis Center Memorial Sloan-Kettering Cancer Center; Genome Data Analysis Center University of Texas MD Anderson Cancer Center; Genome Data Analysis Centers, U. of C., Santa Cruz and the Buck Institute; Biospecimen Core Resource International Genomics Consortium; Nationwide Children’s Hospital Biospecimen Core Resource; Tissue source sites and disease working group. Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487(7407), 330-337.
[http://dx.doi.org/10.1038/nature11252] [PMID: 22810696]

Powell, M.K.; Cempirkova, D.; Dundr, P.; Grimmichova, T.; Trebicky, F.E.; Brown, R.; Gregorova, J.; Litschmannova, M.; Janurova, K.; Pesta, M.; Heneberg, P. Metformin treatment for diabetes mellitus correlates with progression and survival in colorectal carcinoma. Transl. Oncol., 2020, 13(2), 383-392.
[http://dx.doi.org/10.1016/j.tranon.2019.10.011] [PMID: 31896527]

Park, G.B.; Jeong, J.-Y.; Kim, D. GLUT5 regulation by AKT1/3-miR-125b-5p downregulation induces migratory activity and drug resistance in TLR-modified colorectal cancer cells. Carcinogenesis, 2020, 41(10), 1329-1340.
[http://dx.doi.org/10.1093/carcin/bgaa074] [PMID: 32649737]

Lee, G.H.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.O.; Clark, S.K. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. Eur. J. Surg. Oncol., 2015, 41(3), 300-308.
[http://dx.doi.org/10.1016/j.ejso.2014.11.001] [PMID: 25468456]

Loree, J.M.; Pereira, A.A.L.; Lam, M.; Willauer, A.N.; Raghav, K.; Dasari, A.; Morris, V.K.; Advani, S.; Menter, D.G.; Eng, C.; Shaw, K.; Broaddus, R.; Routbort, M.J.; Liu, Y.; Morris, J.S.; Luthra, R.; Meric-Bernstam, F.; Overman, M.J.; Maru, D.; Kopetz, S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin. Cancer Res., 2018, 24(5), 1062-1072.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-2484] [PMID: 29180604]

Dienstmann, R.; Vermeulen, L.; Guinney, J.; Kopetz, S.; Tejpar, S.; Tabernero, J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer, 2017, 17(2), 79-92.
[http://dx.doi.org/10.1038/nrc.2016.126] [PMID: 28050011]

Guinney, J.; Dienstmann, R.; Wang, X.; de Reyniès, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; Bot, B.M.; Morris, J.S.; Simon, I.M.; Gerster, S.; Fessler, E.; De Sousa, E. Melo, F.; Missiaglia, E.; Ramay, H.; Barras, D.; Homicsko, K.; Maru, D.; Manyam, G.C.; Broom, B.; Boige, V.; Perez-Villamil, B.; Laderas, T.; Salazar, R.; Gray, J.W.; Hanahan, D.; Tabernero, J.; Bernards, R.; Friend, S.H.; Laurent-Puig, P.; Medema, J.P.; Sadanandam, A.; Wessels, L.; Delorenzi, M.; Kopetz, S.; Vermeulen, L.; Tejpar, S. The consensus molecular subtypes of colorectal cancer. Nat. Med., 2015, 21(11), 1350-1356.
[http://dx.doi.org/10.1038/nm.3967] [PMID: 26457759]

Thanki, K.; Nicholls, M.E.; Gajjar, A.; Senagore, A.J.; Qiu, S.; Szabo, C.; Hellmich, M.R.; Chao, C. Consensus molecular subtypes of colorectal cancer and their clinical implications. Int. Biol. Biomed. J., 2017, 3(3), 105-111.

Lee, M.S.; Menter, D.G.; Kopetz, S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J. Natl. Compr. Canc. Netw., 2017, 15(3), 411-419.
[http://dx.doi.org/10.6004/jnccn.2017.0038] [PMID: 28275039]

Grady, W.M.; Carethers, J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology, 2008, 135(4), 1079-1099.
[http://dx.doi.org/10.1053/j.gastro.2008.07.076] [PMID: 18773902]

Pino, M.S.; Chung, D.C. The chromosomal instability pathway in colon cancer. Gastroenterology, 2010, 138(6), 2059-2072.
[http://dx.doi.org/10.1053/j.gastro.2009.12.065] [PMID: 20420946]

Yamamoto, S.; Iwakuma, T. Regulators of oncogenic mutant TP53 gain of function. Cancers (Basel), 2018, 11(1), 4.
[http://dx.doi.org/10.3390/cancers11010004] [PMID: 30577483]

Sinicrope, F.A.; Sargent, D.J. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin. Cancer Res., 2012, 18(6), 1506-1512.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1469] [PMID: 22302899]

Boland, C.R.; Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology, 2010, 138(6), 2073-2087.e3.
[http://dx.doi.org/10.1053/j.gastro.2009.12.064] [PMID: 20420947]

Umar, A.; Boland, C.R.; Terdiman, J.P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; Fishel, R.; Lindor, N.M.; Burgart, L.J.; Hamelin, R.; Hamilton, S.R.; Hiatt, R.A.; Jass, J.; Lindblom, A.; Lynch, H.T.; Peltomaki, P.; Ramsey, S.D.; Rodriguez-Bigas, M.A.; Vasen, H.F.; Hawk, E.T.; Barrett, J.C.; Freedman, A.N.; Srivastava, S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst., 2004, 96(4), 261-268.
[http://dx.doi.org/10.1093/jnci/djh034] [PMID: 14970275]

Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.; Widschwendter, M.; Weener, D.; Buchanan, D.; Koh, H.; Simms, L.; Barker, M.; Leggett, B.; Levine, J.; Kim, M.; French, A.J.; Thibodeau, S.N.; Jass, J.; Haile, R.; Laird, P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet., 2006, 38(7), 787-793.
[http://dx.doi.org/10.1038/ng1834] [PMID: 16804544]

Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(12), 686-700.
[http://dx.doi.org/10.1038/nrgastro.2011.173] [PMID: 22009203]

Al-Sohaily, S.; Biankin, A.; Leong, R.; Kohonen-Corish, M.; Warusavitarne, J. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol., 2012, 27(9), 1423-1431.
[http://dx.doi.org/10.1111/j.1440-1746.2012.07200.x] [PMID: 22694276]

Brocardo, M.; Henderson, B.R. APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol., 2008, 18(12), 587-596.
[http://dx.doi.org/10.1016/j.tcb.2008.09.002] [PMID: 18848448]

Herzig, D.O.; Tsikitis, V.L. Molecular markers for colon diagnosis, prognosis and targeted therapy. J. Surg. Oncol., 2015, 111(1), 96-102.
[http://dx.doi.org/10.1002/jso.23806] [PMID: 25297801]

Rennoll, S.; Yochum, G. Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. World J. Biol. Chem., 2015, 6(4), 290-300.
[http://dx.doi.org/10.4331/wjbc.v6.i4.290] [PMID: 26629312]

Toon, C.W.; Chou, A.; Clarkson, A.; DeSilva, K.; Houang, M.; Chan, J.C.; Sioson, L.L.; Jankova, L.; Gill, A.J. Immunohistochemistry for myc predicts survival in colorectal cancer. PLoS One, 2014, 9(2), e87456.
[http://dx.doi.org/10.1371/journal.pone.0087456] [PMID: 24503701]

Chen, J.; Guo, F.; Shi, X.; Zhang, L.; Zhang, A.; Jin, H.; He, Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer, 2014, 14(1), 802.
[http://dx.doi.org/10.1186/1471-2407-14-802] [PMID: 25367198]

Li, W.; Qiu, T.; Zhi, W.; Shi, S.; Zou, S.; Ling, Y.; Shan, L.; Ying, J.; Lu, N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer, 2015, 15(1), 340.
[http://dx.doi.org/10.1186/s12885-015-1345-3] [PMID: 25929517]

Kadowaki, S.; Kakuta, M.; Takahashi, S.; Takahashi, A.; Arai, Y.; Nishimura, Y.; Yatsuoka, T.; Ooki, A.; Yamaguchi, K.; Matsuo, K.; Muro, K.; Akagi, K. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J. Gastroenterol., 2015, 21(4), 1275-1283.
[http://dx.doi.org/10.3748/wjg.v21.i4.1275] [PMID: 25632202]

Day, F.; Muranyi, A.; Singh, S.; Shanmugam, K.; Williams, D.; Byrne, D.; Pham, K.; Palmieri, M.; Tie, J.; Grogan, T.; Gibbs, P.; Sieber, O.; Waring, P.; Desai, J. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target. Oncol., 2015, 10(1), 99-109.
[http://dx.doi.org/10.1007/s11523-014-0319-8] [PMID: 24859797]

Yaeger, R.; Cercek, A.; O’Reilly, E.M.; Reidy, D.L.; Kemeny, N.; Wolinsky, T.; Capanu, M.; Gollub, M.J.; Rosen, N.; Berger, M.F.; Lacouture, M.E.; Vakiani, E.; Saltz, L.B. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res., 2015, 21(6), 1313-1320.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2779] [PMID: 25589621]

Morkel, M.; Riemer, P.; Bläker, H.; Sers, C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget, 2015, 6(25), 20785-20800.
[http://dx.doi.org/10.18632/oncotarget.4750] [PMID: 26299805]

Rosty, C.; Young, J.P.; Walsh, M.D.; Clendenning, M.; Sanderson, K.; Walters, R.J.; Parry, S.; Jenkins, M.A.; Win, A.K.; Southey, M.C.; Hopper, J.L.; Giles, G.G.; Williamson, E.J.; English, D.R.; Buchanan, D.D. PIK₃CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One, 2013, 8(6), e65479.
[http://dx.doi.org/10.1371/journal.pone.0065479] [PMID: 23785428]

Liao, X.; Morikawa, T.; Lochhead, P.; Imamura, Y.; Kuchiba, A.; Yamauchi, M.; Nosho, K.; Qian, Z.R.; Nishihara, R.; Meyerhardt, J.A.; Fuchs, C.S.; Ogino, S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res., 2012, 18(8), 2257-2268.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-2410] [PMID: 22357840]

Atreya, C.E.; Sangale, Z.; Xu, N.; Matli, M.R.; Tikishvili, E.; Welbourn, W.; Stone, S.; Shokat, K.M.; Warren, R.S. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med., 2013, 2(4), 496-506.
[http://dx.doi.org/10.1002/cam4.97] [PMID: 24156022]

Sarli, L.; Bottarelli, L.; Bader, G.; Iusco, D.; Pizzi, S.; Costi, R.; D’Adda, T.; Bertolani, M.; Roncoroni, L.; Bordi, C. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis. Colon Rectum, 2004, 47(9), 1467-1482.
[http://dx.doi.org/10.1007/s10350-004-0628-6] [PMID: 15486743]

Popat, S.; Houlston, R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer, 2005, 41(14), 2060-2070.
[http://dx.doi.org/10.1016/j.ejca.2005.04.039] [PMID: 16125380]

Munro, A.J.; Lain, S.; Lane, D.P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer, 2005, 92(3), 434-444.
[http://dx.doi.org/10.1038/sj.bjc.6602358] [PMID: 15668707]

Rooney, P.H.; Boonsong, A.; McKay, J.A.; Marsh, S.; Stevenson, D.A.; Murray, G.I.; Curran, S.; Haites, N.E.; Cassidy, J.; McLeod, H.L. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br. J. Cancer, 2001, 85(10), 1492-1498.
[http://dx.doi.org/10.1054/bjoc.2001.2095] [PMID: 11720434]

Jose, J.; Kumar, R.; Harilal, S.; Mathew, G.E.; Prabhu, A.; Uddin, M.S.; Aleya, L.; Kim, H.; Mathew, B. Magnetic nanoparticles for hyperthermia in cancer treatment: an emerging tool. Environ. Sci. Pollut. Res. Int., 2020, 27(16), 19214-19225.
[http://dx.doi.org/10.1007/s11356-019-07231-2] [PMID: 31884543]

Kumar, R.; Harilal, S.; Gupta, S.V.; Jose, J.; Thomas Parambi, D.G.; Uddin, M.S.; Shah, M.A.; Mathew, B. Exploring the new horizons of drug repurposing: a vital tool for turning hard work into smart work. Eur. J. Med. Chem., 2019, 182, 111602.
[http://dx.doi.org/10.1016/j.ejmech.2019.111602] [PMID: 31421629]

Van Cutsem, E.; Nordlinger, B.; Cervantes, A. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann. Oncol., 2010, 21(suppl_5), v93-v97.
[http://dx.doi.org/10.1093/annonc/mdq222] [PMID: 20555112]

Palmieri, L-J.; Mineur, L.; Tougeron, D.; Rousseau, B.; Granger, V.; Gornet, J-M.; Smith, D.; Lievre, A.; Galais, M-P.; Doat, S.; Pernot, S.; Bignon-Bretagne, A.L.; Metges, J.P.; Baba-Hamed, N.; Michel, P.; Obled, S.; Vitellius, C.; Bouche, O.; Saban-Roche, L.; Buecher, B.; des Guetz, G.; Locher, C.; Trouilloud, I.; Goujon, G.; Dior, M.; Manfredi, S.; Soularue, E.; Phelip, J.M.; Henriques, J.; Vernery, D.; Coriat, R. Withholding the introduction of anti-epidermal growth factor receptor: impact on outcomes in RAS wild- type metastatic colorectal tumors: a multicenter AGEO study (the WAIT or ACT Study). Oncologist, 2020, 25(2), e266-e275.
[http://dx.doi.org/10.1634/theoncologist.2019-0328] [PMID: 32043796]

Venook, A. Gastrointestinal cancer. Oncologist, 2005, 10(4), 250-261.
[http://dx.doi.org/10.1634/theoncologist.10-4-250] [PMID: 15821245]

Vincenzi, B.; Santini, D.; Rabitti, C.; Coppola, R.; Beomonte Zobel, B.; Trodella, L.; Tonini, G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br. J. Cancer, 2006, 94(6), 792-797.
[http://dx.doi.org/10.1038/sj.bjc.6603018] [PMID: 16508634]

CAPOX. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/capox (Accessed date: 10th September 2020).

FOLFIRI. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/folfiri (Accessed date: 10th September 2020).

FOLFIRI-BEVACIZUMAB. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/ treatment/drugs/folfiri-bevacizumab (Accessed date: 10th September 2020).

FOLFIRI-CETUXIMAB. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/folfiri-cetuximab (Accessed date: 10th September 2020).

FOLFOX. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/folfox (Accessed date: 10th September 2020).

FU-LV. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/fu-lv (Accessed date: 10th September 2020).

XELIRI. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/xeliri (Accessed date: 10th September 2020).

XELOX. National Cancer Institute (NIH). Available at: https://www.cancer.gov/about-cancer/treatment/drugs/xelox (Accessed date: 10th September 2020).

Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S.D.; Chang, D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(10), 1626-1634.
[http://dx.doi.org/10.1200/JCO.2007.14.7116] [PMID: 18316791]

Giusti, R.M.; Shastri, K.A.; Cohen, M.H.; Keegan, P.; Pazdur, R. FDA drug approval summary: panitumumab (Vectibix). Oncologist, 2007, 12(5), 577-583.
[http://dx.doi.org/10.1634/theoncologist.12-5-577] [PMID: 17522246]

LeBlanc, J.G.; Levit, R.; Savoy de Giori, G.; de Moreno de LeBlanc, A. Application of vitamin-producing lactic acid bacteria to treat intestinal inflammatory diseases. Appl. Microbiol. Biotechnol., 2020, 104(8), 3331-3337.
[http://dx.doi.org/10.1007/s00253-020-10487-1] [PMID: 32112134]

Kahouli, I.; Tomaro-Duchesneau, C.; Prakash, S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J. Med. Microbiol., 2013, 62(Pt 8), 1107-1123.
[http://dx.doi.org/10.1099/jmm.0.048975-0] [PMID: 23558140]

Chong, E.S.L. A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action. World J. Microbiol. Biotechnol., 2014, 30(2), 351-374.
[http://dx.doi.org/10.1007/s11274-013-1499-6] [PMID: 24068536]

Zhong, L.; Zhang, X.; Covasa, M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J. Gastroenterol., 2014, 20(24), 7878-7886.
[http://dx.doi.org/10.3748/wjg.v20.i24.7878] [PMID: 24976724]

Pala, V.; Sieri, S.; Berrino, F.; Vineis, P.; Sacerdote, C.; Palli, D.; Masala, G.; Panico, S.; Mattiello, A.; Tumino, R.; Giurdanella, M.C.; Agnoli, C.; Grioni, S.; Krogh, V. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int. J. Cancer, 2011, 129(11), 2712-2719.
[http://dx.doi.org/10.1002/ijc.26193] [PMID: 21607947]

Chen, C-C.; Lin, W-C.; Kong, M-S.; Shi, H.N.; Walker, W.A.; Lin, C-Y.; Huang, C-T.; Lin, Y-C.; Jung, S-M.; Lin, T-Y. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br. J. Nutr., 2012, 107(11), 1623-1634.
[http://dx.doi.org/10.1017/S0007114511004934] [PMID: 21992995]

Choi, S.S.; Kim, Y.; Han, K.S.; You, S.; Oh, S.; Kim, S.H. Effects of Lactobacillus strains on cancer cell proliferation and oxidative stress in vitro. Lett. Appl. Microbiol., 2006, 42(5), 452-458.
[http://dx.doi.org/10.1111/j.1472-765X.2006.01913.x] [PMID: 16620202]

Sah, B.N.P.; Vasiljevic, T.; McKechnie, S.; Donkor, O.N. Effect of probiotics on antioxidant and antimutagenic activities of crude peptide extract from yogurt. Food Chem., 2014, 156, 264-270.
[http://dx.doi.org/10.1016/j.foodchem.2014.01.105] [PMID: 24629967]

Morales-Oyarvide, V.; Meyerhardt, J.A.; Ng, K. Vitamin D and physical activity in patients with colorectal cancer: epidemiological evidence and therapeutic implications. Cancer J., 2016, 22(3), 223-231.
[http://dx.doi.org/10.1097/PPO.0000000000000197] [PMID: 27341603]

Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol., 2014, 740, 364-378.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]

Muhammad, N.; Guo, Z. Metal-based anticancer chemotherapeutic agents. Curr. Opin. Chem. Biol., 2014, 19, 144-153.
[http://dx.doi.org/10.1016/j.cbpa.2014.02.003] [PMID: 24608084]

Komeda, S.; Casini, A. Next-generation anticancer metallodrugs. Curr. Top. Med. Chem., 2012, 12(3), 219-235.
[http://dx.doi.org/10.2174/156802612799078964] [PMID: 22236158]

Kelland, L.R. Cisplatin-based anticancer agents. Uses of Inorganic Chemistry in Medicine; Royal Society of Chemistry: Cambridge, 1999, pp. 109-123.

Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4(4), 307-320.
[http://dx.doi.org/10.1038/nrd1691] [PMID: 15789122]

de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000, 18(16), 2938-2947.
[http://dx.doi.org/10.1200/JCO.2000.18.16.2938] [PMID: 10944126]

Hoff, P.M.; Saad, E.D.; Costa, F.; Coutinho, A.K.; Caponero, R.; Prolla, G.; Gansl, R.C. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin. Colorectal Cancer, 2012, 11(2), 93-100.
[http://dx.doi.org/10.1016/j.clcc.2011.10.004] [PMID: 22154408]

Ciombor, K.K.; Wu, C.; Goldberg, R.M. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med., 2015, 66, 83-95.
[http://dx.doi.org/10.1146/annurev-med-051513-102539] [PMID: 25341011]

Hu, C.; Li, X.; Wang, W.; Zhang, R.; Deng, L. Metal-N-heterocyclic carbene complexes as anti-tumor agents. Curr. Med. Chem., 2014, 21(10), 1220-1230.
[http://dx.doi.org/10.2174/0929867321666131217161849] [PMID: 24350852]

Kim, J.H.; Reeder, E.; Parkin, S.; Awuah, S.G. Gold(I/III)-phosphine complexes as potent antiproliferative agents. Sci. Rep., 2019, 9(1), 12335.
[http://dx.doi.org/10.1038/s41598-019-48584-5] [PMID: 31451718]

Lum, C.T.; Wong, A.S-T.; Lin, M.C.; Che, C-M.; Sun, R.W-Y.A. A gold(III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells. Chem. Commun. (Camb.), 2013, 49(39), 4364-4366.
[http://dx.doi.org/10.1039/C2CC37366A] [PMID: 23223325]

Schmitt, S.M.; Frezza, M.; Dou, Q.P. New applications of old metal-binding drugs in the treatment of human cancer. Front. Biosci. (Schol. Ed.), 2012, 4, 375-391.
[http://dx.doi.org/10.2741/s274] [PMID: 22202066]

Tsuji, P.A.; Carlson, B.A.; Yoo, M-H.; Naranjo-Suarez, S.; Xu, X-M.; He, Y.; Asaki, E.; Seifried, H.E.; Reinhold, W.C.; Davis, C.D.; Gladyshev, V.N.; Hatfield, D.L. The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS One, 2015, 10(4), e0124487.
[http://dx.doi.org/10.1371/journal.pone.0124487] [PMID: 25886253]

Huang, H.; Liao, Y.; Liu, N.; Hua, X.; Cai, J.; Yang, C.; Long, H.; Zhao, C.; Chen, X.; Lan, X.; Zang, D.; Wu, J.; Li, X.; Shi, X.; Wang, X.; Liu, J. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget, 2016, 7(3), 2796-2808.
[http://dx.doi.org/10.18632/oncotarget.6425] [PMID: 26625200]

Shi, J.; Nawaz, H.; Pohorly, J.; Mittal, G.; Kakuda, Y.; Jiang, Y. Extraction of polyphenolics from plant material for functional foods- engineering and technology. Food Rev. Int., 2005, 21(1), 139-166.
[http://dx.doi.org/10.1081/FRI-200040606]

Shahidi, F.; Ambigaipalan, P. Phenolics and polyphenolics in foods, beverages and spices: antioxidant activity and health effects- a review. J. Funct. Foods, 2015, 18, 820-897.
[http://dx.doi.org/10.1016/j.jff.2015.06.018]

Jiménez, S.; Gascón, S.; Luquin, A.; Laguna, M.; Ancin-Azpilicueta, C.; Rodríguez-Yoldi, M.J. Rosa canina extracts have antiproliferative and antioxidant effects on Caco-2 human colon cancer. PLoS One, 2016, 11(7), e0159136.
[http://dx.doi.org/10.1371/journal.pone.0159136] [PMID: 27467555]

Yang, B.; McCullough, M.L.; Gapstur, S.M.; Jacobs, E.J.; Bostick, R.M.; Fedirko, V.; Flanders, W.D.; Campbell, P.T. Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: the cancer prevention Study-II Nutrition Cohort. J. Clin. Oncol., 2014, 32(22), 2335-2343.
[http://dx.doi.org/10.1200/JCO.2014.55.3024] [PMID: 24958826]

Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA, 2009, 302(6), 649-658.
[http://dx.doi.org/10.1001/jama.2009.1112] [PMID: 19671906]

Liao, X.; Lochhead, P.; Nishihara, R.; Morikawa, T.; Kuchiba, A.; Yamauchi, M.; Imamura, Y.; Qian, Z.R.; Baba, Y.; Shima, K.; Sun, R.; Nosho, K.; Meyerhardt, J.A.; Giovannucci, E.; Fuchs, C.S.; Chan, A.T.; Ogino, S. Aspirin use, tumor PIK₃CA mutation, and colorectal-cancer survival. N. Engl. J. Med., 2012, 367(17), 1596-1606.
[http://dx.doi.org/10.1056/NEJMoa1207756] [PMID: 23094721]

Janakiram, N.B.; Rao, C.V. The role of inflammation in colon cancer. Inflamm. Cancer; Springer, 2014, pp. 25-52.
[http://dx.doi.org/10.1007/978-3-0348-0837-8_2]

Rigau, J.; Piqué, J.M.; Rubio, E.; Planas, R.; Tarrech, J.M.; Bordas, J.M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med., 1991, 115(12), 952-954.
[http://dx.doi.org/10.7326/0003-4819-115-12-952] [PMID: 1659272]

Suh, N.; Reddy, B. S.; DeCastro, A.; Paul, S.; Lee, H. J.; Smolarek, A. K.; So, J. Y.; Simi, B.; Wang, C. X.; Janakiram, N. B. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the P65/β-Catenin/Cyclin D1 signaling pathway in rats. Cancer Prev. Res. (Phila. Pa.), 2011, 4(11), 1895-1902.
[http://dx.doi.org/10.1158/1940-6207.CAPR-11-0222] [PMID: 21764859]

Ungprasert, P.; Cheungpasitporn, W.; Crowson, C.S.; Matteson, E.L. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur. J. Intern. Med., 2015, 26(4), 285-291.
[http://dx.doi.org/10.1016/j.ejim.2015.03.008] [PMID: 25862494]

Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 2001, 1(1), 11-21.
[http://dx.doi.org/10.1038/35094017] [PMID: 11900248]

Jüni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P.A.; Egger, M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 2004, 364(9450), 2021-2029.
[http://dx.doi.org/10.1016/S0140-6736(04)17514-4] [PMID: 15582059]

Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284(10), 1247-1255.
[http://dx.doi.org/10.1001/jama.284.10.1247] [PMID: 10979111]

Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352(11), 1071-1080.
[http://dx.doi.org/10.1056/NEJMoa050405] [PMID: 15713944]

McDonald, B.F.; Quinn, A.M.; Devers, T.; Cullen, A.; Coulter, I.S.; Marison, I.W.; Loughran, S.T. In vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer. J. Pharm. Pharmacol., 2015, 67(5), 685-695.
[http://dx.doi.org/10.1111/jphp.12372] [PMID: 25650335]

Lev-Ari, S.; Strier, L.; Kazanov, D.; Madar-Shapiro, L.; Dvory-Sobol, H.; Pinchuk, I.; Marian, B.; Lichtenberg, D.; Arber, N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res., 2005, 11(18), 6738-6744.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0171] [PMID: 16166455]

Smith, B.H.; Gazda, L.S.; Conn, B.L.; Jain, K.; Asina, S.; Levine, D.M.; Parker, T.S.; Laramore, M.A.; Martis, P.C.; Vinerean, H.V.; David, E.M.; Qiu, S.; North, A.J.; Couto, C.G.; Post, G.S.; Waters, D.J.; Cordon-Cardo, C.; Hall, R.D.; Gordon, B.R.; Diehl, C.H.; Stenzel, K.H.; Rubin, A.L. Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth. Cancer Res., 2011, 71(3), 725-735.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2258] [PMID: 21266362]

Ocean, A.J.; Parikh, T.; Berman, N.; Escalon, J.; Shah, M.A.; Andrada, Z.; Akahoho, E.; Pogoda, J.M.; Stoms, G.B.; Escobia, V.B.; Ruggiero, J.T.; Fahey, T.J.; Smith, B.H. Phase I/II Trial of Intraperitoneal Implantation of Agarose-Agarose Macrobeads (MB) Containing Mouse Renal Adenocarcinoma Cells (RENCA) in Patients (Pts) with Advanced Colorectal Cancer (CRC) Am. Soc. Clin. Onco., 2013, 13(15_SUPPL), e14517.
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14517]